Task Force on Implementation of HbA1c Standardization (Integrated Project) (TF-HbA1c)
(Closed in 2016)
Membership
| Name | Position | Country | Term | Time in Office |
| G. John | Chair | UK | 2nd | 2013 01 - 2015 12 |
| C. Weykamp | Secretary | NL | 2nd | 2013 01 - 2015 12 |
| E. English | Member | UK | 1st | 2013 06 - 2015 12 |
| L. Ji | Member | CN | 1st | 2012 01 - 2014 12 |
| E. Lenters-Westra | Member | NL | 1st | 2013 03 - 2015 12 |
| R. Little | Member | US | 2nd | 2012 01 - 2014 12 |
| G. Roglic | Member | CH | 1st | 2013 06 - 2015 12 |
| D. Sacks | Member | US | 2nd | 2012 01 - 2014 12 |
| I. Takei | Member | JP | 2nd | 2012 01 - 2014 12 |
| P. Gillery | SD Liaison | FR |
The Task Force for HbA1C (TF-HbA1c) is an Integrated Project that involves input from a number of IFCC functional units and also from clinical experts in the field of diabetes.
Link to the IFCC HbA1c Network Webpage
Aim
To establish an interface between IFCC and its National / Corporate Members and the clinical users of HbA1C to enable the implementation of a scientifically sound reporting structure for HbA1C standardised to the IFCC Reference Measurement Procedure.
Objectives
- To establish a small group of clinical and scientific experts (maximum of 5); consider geographical balance.
- To act as an advisory board to the HbA1C Reference Laboratory Network.
- Develop scientific links between National Networks.
- Advise manufacturers on delivery objectives.
- To establish links with professional bodies (scientific and clinical) to enable transition of reportable HbA1C values.
- To help implement the consensus statement.
- Monitor the introduction of the Consensus statement globally.
- Develop quality targets for the measurement of HbA1C, and on basis of these targets, and in conjunction with professional bodies, advise on the use of HbA1c for monitoring, diagnosis and screening of diabetes and glucose intolerance
Delivery
- Develop educational material; consider translating into various languages (e learning).
- Monitor developments through surveys.
- Attend international / National meetings to provide advice and guidance based on best practice.
- Work with Manufacturers.
- Work with scientific bodies to establish workshops.
- Develop a website.
Accountability
The TF-HbA1C will report to the Executive Board through the President.
List of addresses
Chair
Dr. Garry JOHN
Consultant Clinical Biochemist
and Head of Clinical Biochemistry
Norfolk and Norwich University Hospital
UK
Tel: +44 (0) 1603 286 933
Members
Dr. Cas WEYKAMP
Queen Beatrix Hospital
Beatrixpark 1
7101 BN Winterswijk
The Netherlands
Tel.: + 31 543 544774
Dr. Emma English
School of Graduate Entry Medicine and Health
University of Nottingham
Royal Derby Hospital
DE22 3DT
UK
Tel: +44 1332 724620
Dr. L. JI
China
Dr. Erna LENTERS-WESTRA
HbA1c research coordinator
Isala
Clinical Chemistry Department
Buiding:Vlinder 1, Room: V1.2.627
Dokter van Heesweg 2
8025 AB ZWOLLE
The Netherlands
Tel.: +31384247803
Dr. Randie R. LITTLE
University of Missouri School of Medicine
Departments of Pathology and Anatomical
Sciences and Child Health
M767, 1 Hospital Dr.
Columbia, MO 65212
USA
Tel.: +1 573-882-1257
Dr. Gojka Roglic
Department of Management of Noncommunicable Diseases
World Health Organization
Geneva
Switzerland
Phone: +41 22 791 4306
Fax: +41 22 791 4775
Dr. David B. SACKS
Associate Professor of Pathology
Harvard Medical School
Brigham and Women`s Hospital
Thorn 530
75 Francis St
Boston, MA 02115
USA
Prof. Izumi TAKEI
Director for diabetes and endocrinology
Ichikawa General Hospital
Tokyo Dental College
5-11-13,Sugano,
Ichikawa-city, Chiba 272-8513
Japan
Phone:+81-47-322-0151
Fax:+81-47-325-4456